DE69735643D1 - IL12 zur Gentherapie der Tumoren - Google Patents

IL12 zur Gentherapie der Tumoren

Info

Publication number
DE69735643D1
DE69735643D1 DE69735643T DE69735643T DE69735643D1 DE 69735643 D1 DE69735643 D1 DE 69735643D1 DE 69735643 T DE69735643 T DE 69735643T DE 69735643 T DE69735643 T DE 69735643T DE 69735643 D1 DE69735643 D1 DE 69735643D1
Authority
DE
Germany
Prior art keywords
tumors
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735643T
Other languages
English (en)
Other versions
DE69735643T2 (de
Inventor
L Rakhmilevich
Ning-Sun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of DE69735643D1 publication Critical patent/DE69735643D1/de
Publication of DE69735643T2 publication Critical patent/DE69735643T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69735643T 1996-06-05 1997-06-04 IL12 zur Gentherapie der Tumoren Expired - Fee Related DE69735643T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/659,206 US5922685A (en) 1996-06-05 1996-06-05 IL-12 gene therapy of tumors
US659206 1996-06-05
PCT/US1997/009591 WO1997046263A1 (en) 1996-06-05 1997-06-04 Il-12 gene therapy of tumors

Publications (2)

Publication Number Publication Date
DE69735643D1 true DE69735643D1 (de) 2006-05-18
DE69735643T2 DE69735643T2 (de) 2006-12-14

Family

ID=24644498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735643T Expired - Fee Related DE69735643T2 (de) 1996-06-05 1997-06-04 IL12 zur Gentherapie der Tumoren

Country Status (7)

Country Link
US (1) US5922685A (de)
EP (1) EP0963207B1 (de)
JP (1) JP2000512980A (de)
DE (1) DE69735643T2 (de)
ES (1) ES2262180T3 (de)
HK (1) HK1024622A1 (de)
WO (1) WO1997046263A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US6423308B1 (en) * 1998-09-15 2002-07-23 Wyeth Treatment of Kaposi's sarcoma with IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20030190305A1 (en) * 1999-09-15 2003-10-09 Wyeth And National Institutes Of Health Treatment of Kaposi's sarcoma with IL-12
ATE285806T1 (de) 1999-10-11 2005-01-15 Felton International Inc Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
MXPA02012734A (es) * 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) * 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
AU2008311292B9 (en) * 2007-10-08 2014-10-09 Intrexon Corporation Engineered dendritic cells and uses for the treatment of cancer
KR101361416B1 (ko) 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
US8556882B2 (en) 2009-04-30 2013-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
WO2010147971A2 (en) * 2009-06-15 2010-12-23 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
HRP20230050T1 (hr) 2016-05-18 2023-03-03 Modernatx, Inc. Polinukleotidi koji kodiraju interleukin-12 (il12) i njihova upotreba
EP3625246A1 (de) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynukleotide zur codierung von gebundenen interleukin-12 (il12)-polypeptiden und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5015580A (en) * 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
EP0690732B1 (de) * 1994-01-21 2003-01-29 Powderject Vaccines, Inc. Gasbetätigtes element zum austragen von genmaterial
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses

Also Published As

Publication number Publication date
JP2000512980A (ja) 2000-10-03
DE69735643T2 (de) 2006-12-14
EP0963207A1 (de) 1999-12-15
WO1997046263A1 (en) 1997-12-11
US5922685A (en) 1999-07-13
EP0963207B1 (de) 2006-04-05
EP0963207A4 (de) 2003-01-22
HK1024622A1 (en) 2000-10-20
ES2262180T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
DE69739418D1 (de) System zur Herstimulussteuerung
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
DE4290881T1 (de) Verfahren zur Massage der Wirbelsäulengegend
DE69738119D1 (de) Ballonkatheter zur photodynamischen Therapie
GB9622500D0 (en) Therapeutic gene
NO994009D0 (no) Gensekvensator og metoder
ID18679A (id) Penggunaan terapi lanjutan
DE69710502D1 (de) Gerät zur gewebestimulation
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
PT907358E (pt) Terapia de distribuicao uniforme de droga
ZA983608B (en) Leptin as an inhibitor of tumor cell proliferation
ATE218355T1 (de) Verwendung von mycobacterium zur tumorbehandlung
FI972066A0 (fi) Uusi kasvainten suppressorigeeni HIC-1
DE69729099D1 (de) Amine zur herstellung von medikamenten zur hemmung der tumorzellenvermehrung
NO986177D0 (no) FremgangsmÕte for fremstilling av terapeutisk DNA
DE59510240D1 (de) Hochfrequenztherapieeinrichtung zur interstitiellen Thermotherapie von Tumoren
DK1083934T3 (da) Genterapifremgangsmåder
AU6450398A (en) Sr-bi regulatory sequences and therapeutic methods of use
EP1039883A4 (de) Verfahren zur behandlung apolipoprotein e bedingter krankheiten
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69733865D1 (de) Herzschrittmacher mit verbesserter Verteilung der Reizungsfrequenz
IL126970A0 (en) Stimulation of host defense mechanisms against tumors
ID24922A (id) Terapi kombinasi untuk pengobatan aids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee